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Abstract
Background/objectives To investigate the impact of non-neovascular (dry) age-related macular degeneration (AMD) on the
person with respect to diagnosis, vision loss and coping strategies.
Subjects/methods Volunteers with dry AMD with a range of disease severity were given an eye examination and asked to
describe aspects of their experience with dry AMD in a semi-structured interview. Interviews were audio-recorded, tran-
scribed, and subjected to Framework analysis. Overarching themes were pre-deﬁned, whilst subthemes were derived from
the data.
Results Twenty-seven participants (81% female), with early (n= 3), intermediate (n= 16) and advanced dry AMD (GA;
n= 8) were interviewed. Median (interquartile range) age (years), logMAR binocular visual acuity and Pelli−Robson
contrast sensitivity were 76 (71, 80), 0.2 (0.18, 0.40) and 1.65 (1.35, 1.93), respectively. Overarching themes (and sub-
themes) were: diagnosis (relationship with healthcare professional, psychological impact of diagnosis, and knowledge of
AMD, both pre- and post-diagnosis), impact of visual loss (functional and psychological) and coping strategies (help from
others and personal strategies). Many participants reported feelings of distress at the time of diagnosis and, particularly
noteworthy, several reported a constant fear of their condition worsening.
Conclusions Dry AMD, for which there is currently no treatment, can have a signiﬁcant impact on individuals, even in its
early stages, before signiﬁcant functional vision loss is manifest, as well as in its intermediate and advanced stages. Results
from this study offer important insight into the experience of living with dry AMD not previously explored. Moreover, the
results have the potential to serve as an educational resource for eyecare professionals.
Introduction
Non-neovascular, or dry age-related macular degeneration
(AMD) is a gradually progressive, incurable, sight-
threatening condition. Whilst several studies have investi-
gated the impact of living with other eye conditions,
including neovascular AMD (nAMD) [1, 2], the impact of
living with dry AMD remains relatively neglected in the
literature. Effects of dry AMD on performance of activities
of daily living are now becoming better appreciated through
both patient-reported outcome measures and performance-
based studies [3]. However, a more explorative approach to
understanding the experience of people living with a con-
dition is through qualitative methods [4]. Qualitative
research has potential to add important knowledge as well
as shape future research and practice [5–8]. Yet studies
adopting qualitative methodologies are underrepresented in
ophthalmology journals [9].
Our recent systematic review [3] evidenced the scarcity
of qualitative research focusing on the patient experience of
AMD [10–20]. Moreover, only two studies [10, 11] repor-
ted speciﬁcally on participants with dry AMD. Of these, one
[10] had only six participants with dry AMD and two of the
four themes identiﬁed in the results related only to partici-
pants with nAMD. The other [11] reports just one case
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study of a person living with nAMD and their partner living
with dry AMD.
Onset of visual impairment in nAMD tends to be sudden
whereas that of dry AMD is more gradual. In most cases,
vision in wet AMD may be maintained or improved with
use of intra-vitreal anti-VEGF injections, whilst dry AMD
remains untreatable. As such, the patient experience in dry
AMD differs from that of wet AMD. For example, previous
qualitative research [10] reports optimism amongst patients
whose nAMD allows them to be treated although the
invasive nature of nAMD treatment may be associated with
negative effects on quality of life [2, 10]. Furthermore, the
insidious nature of dry AMD means that diagnosis may
occur before the patient is aware of any visual disturbances.
We suggest that this may have a psychological impact on
the patient which differs to that of nAMD. We propose that
the patient journey in dry AMD is unique and worthy of
further investigation; this is therefore the subject of
this study.
We aim to explore the patient experience of dry AMD,
with particular emphasis on diagnosis and impact on
everyday life of the condition as well as coping strategies
developed.
Methods
Participant recruitment, baseline clinical
examination, and ethical approval
People with dry AMD were recruited from Moorﬁelds Eye
Hospital Trust, London, optometrists local to the study
institution and the membership of the Macular Society
(www.macularsociety.org). Participants were required to be
aged ≥ 60 years, have sufﬁciently clear ocular media, ade-
quate pupillary dilation and ﬁxation to allow quality fundus
imaging (Lens Opacities Classiﬁcation System (LOCS) III
grading scale [21] of grade <3), and to have dry AMD in
their better-seeing eye. Fellow eyes were permitted to be of
any AMD status because the impact of the better-seeing eye
has been found to have a stronger relationship with vision-
related quality of life than the worse-seeing eye [22–24].
Binocular VA was required to be logMAR 0.7 or better
(Snellen equivalent of 6/30) as measured using an Early
Treatment Diabetic Retinopathy Study (ETDRS) chart.
Participants were excluded if they had nAMD in their
better-seeing eye, ocular or systemic diseases other than
AMD that could affect visual function or history of medi-
cation known to affect macular function, or high risk of
angle closure during pupillary dilation (Van Herick < Grade
2, history of angle closure or experience of prodromal
symptoms of angle closure). In addition, participants were
required to pass an abridged version of the Mini Mental
State Evaluation [25] which has been used in previous
vision science research [26, 27] and to have sufﬁcient
knowledge of the English language to understand the Par-
ticipant Information Sheet and carry out a semi-structured
interview with the researcher.
The study was approved by Nottingham 2 National
Health Service (NHS) Research Ethics Committee (15/EM/
0063) and was conducted according to the tenets of the
Declaration of Helsinki. Written, informed consent was
obtained from each participant prior to examination. Parti-
cipant information was anonymised before being entered
into a secure computer database.
After providing informed consent, participants under-
went baseline examinations to evaluate their AMD status
and to ensure eligibility for participation. Structured history
and symptoms were taken to assess general health.
Best-corrected visual acuity (VA) was recorded using the
ETDRS chart. This was scored per letter (and in logMAR
format) and participants were encouraged to read down the
chart until they were unable to read three out of a possible
ﬁve letters on a line. Contrast sensitivity (CS) was tested
with the Pelli−Robson chart at 1 m (binocularly) with
best‐corrected distance prescription. This was scored per
letter (if participants read ‘C’ instead of ‘O’ or vice versa
this was counted as correct).
Following the interview, participants underwent dilated
fundus examination. Lens clarity (LOCS III) [15] and
anterior chamber angle (Van Herick) were graded using the
slit lamp biomicroscope. Digital colour fundus photographs
were obtained and these were used to classify and grade
AMD status by the better-seeing eye (determined by VA) as
early, intermediate, or advanced according to the Beckman
classiﬁcation scale [30]. This widely used scale grades
macular disease status according to drusen size, pigmentary
abnormalities, and presence or absence of geographic
atrophy (GA) or nAMD. Spectral-domain optical coherence
tomography and fundus autoﬂuorescence images were
taken using a Spectralis (Heidelberg Engineering, Heidel-
berg, Germany).
Interview procedure
Semi-structured interviews were conducted and audio-
recorded between May 2015 and February 2016. Inter-
views were based on a topic guide (see Supplementary
File 1) that was written prior to the start of the study. Topic
guide questions were initially based on their previous use
[6], adapted to the current study aims, and reﬁned further
after an initial pilot interview. Interview questions were open
ended and asked in such a way that required minimal
interviewer input and encouraged detailed responses from
participants. Care was taken not to ask leading questions,
although prompts were used to encourage participants to
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expand on a point, or to clarify a question where it appeared
that the participant may have misunderstood the interviewer.
Efforts were made to ensure that participants were describ-
ing experiences relating to their corrected vision; i.e. when
wearing their refractive correction. It was emphasised prior
to the interview that there were no right or wrong answers
and that participants would be given the opportunity to
expand on or clarify any points at the end of the interview.
All interviews were conducted in person at City, Uni-
versity of London by the lead author (a female optometrist;
DJT). The majority of interviews were conducted in a study
room, with only the participant and researcher present, but a
small number of participants chose to have a friend or
family member present in the room. The researcher corre-
sponded with participants via email and telephone during
the recruitment process but had never met them in person
before the study visit. Participants’ travel expenses were
reimbursed. The study followed the Consolidated Criteria
for Reporting Qualitative Research (COREQ) [28].
Analysis
Transcribed data were analysed by one of the authors (DJT)
using Framework analysis [29]. Transcripts were read and re-
read, themes were identiﬁed, and example quotes were chosen
to illustrate these themes. Overarching themes were deﬁned
by the study aims, whilst subthemes were derived from the
data. A second researcher (LJ) independently read and ana-
lysed a subset (20%) of the transcripts, and reviewed the
completed Framework chart. Any differences of opinion
regarding meaning of sentences or importance of themes were
discussed until a consensus was reached. The qualitative
software package NVIVO V.11 (QSR International, Cam-
bridge, Massachusetts, USA) was used for data management.
The themes emerging from the interviews are illustrated
with direct quotes from the transcripts, which are presented
in italicised font. Each quotation is followed by a code
where the ﬁrst initial represents AMD stage (E= Early, I=
Intermediate, A=Advanced) and the second initial repre-
sents gender (F= Female, M=Male).
Results
Participants
Twenty-seven participants (81% female) were interviewed.
Demographic and clinical information for each individual
participant is shown in Table 1. Median (interquartile range
(IQR)) age was 76 (71, 80) years. Median (IQR) logMAR
binocular VA and Pelli−Robson CS were 0.2 (0.18, 0.40)
and 1.65 (1.35, 1.93), respectively. Better and worse eye
median (IQR) logMAR VA was 0.26 (0.19, 0.40) and 0.40
(0.30, 0.95) respectively. Three patients had early AMD, 16
had intermediate AMD and eight patients had advanced
AMD (GA) according to the Beckman Classiﬁcation [30] in
their better-seeing eye. Interviews lasted a median (IQR) of
15 min (12, 21 min).
Impact of AMD
Data were coded into three overarching themes relating to
the experience of dry AMD: diagnosis, impact on everyday
life, and coping strategies. The main themes and subthemes
are summarised in Fig. 1.
Diagnosis
Diagnoses initiated from a variety of different care settings;
from routine eye examinations with the patient’s optome-
trist, non-routine examination with an optometrist or general
practitioner (GP) after noticing problems with vision, or in
the emergency room after noticing visual problems (either
related or unrelated to AMD):
‘I did not have any real difﬁculties until … I was
driving along a road and I did not realise that it was
now in both eyes … there was a lady halfway across
and I couldn’t see her because of the blind
spot.’ (AM1)
‘Well it was the optician who pointed it out to me, I
wouldn’t have known.’ (EF1)
‘I went for a regular eye test and the optician told me
that she had a machine … and she used it. When I did
that, it was diagnosed.’ (EF2)
‘I’d just simply gone for an eye test just to get new
glasses.’ (IF10)
‘I had a big black ﬂoater … I was frightened about
that, I thought I’d got a detached retina… I rang my
GP who said go the A&E and A&E … told me that
that was a ﬂoater and nothing to worry about but that
I had the beginnings of macular degeneration’. (EF3)
‘I couldn’t understand why I couldn’t see clear
enough. The optician said you have cataracts and I
thought great, because when I went up to see the
consultant I expected him to turn round to me and say
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Fig. 1 Diagram showing the main themes and subthemes that emerged from the analysis, and how different categories relate to each other
Table 1 Demographic and clinical characteristics of participants
ID Gender AMD stage Age Binocular VA Better eye VA Worse eye VA CS
EF1 Female Early 84 0.28 0.38 0.46 1.5
EF2 Female Early 69 0.2 0.1 0.3 1.95
EF3 Female Early 77 0.18 0.18 0.3 1.65
IF1 Female Intermediate 86 0.1 0.26 0.26 1.65
IF14 Female Intermediate 76 0.1 0.12 0.32 1.95
IF2 Female Intermediate 74 0.24 0.22 0.86 1.5
IF3 Female Intermediate 61 0.02 −0.04 −0.02 1.95
IF4 Female Intermediate 78 0.2 0.2 0.4 1.9
IF5 Female Intermediate 74 0.2 0.2 0.26 1.95
IF6 Female Intermediate 82 0.26 0.22 1.58 1.35
IF6 Female Intermediate 77 0.44 0.4 0.8 1.35
IF7 Female Intermediate 81 0.44 0.44 0.46 1.95
IF8 Female Intermediate 62 0.2 0.3 0.3 1.65
IF9 Female Intermediate 79 0.3 0.4 0.48 1.55
IM1 Male Intermediate 70 0.1 0.06 0.1 1.95
IF10 Female Intermediate 69 0.1 0.1 0.12 1.95
IF11 Female Intermediate 86 0.66 0.6 1.58 0.9
IF12 Female Intermediate 72 0.18 0.16 0.36 1.65
IF13 Female Intermediate 76 0.16 0.2 0.32 1.8
AM1 Male Advanced 75 0.58 0.58 2 0.25
AM2 Male Advanced 77 0.2 0.3 0.34 1.65
AF1 Female Advanced 68 0.2 0.22 1.04 1.65
AF2 Female Advanced 73 0.52 0.58 1.04 0.3
AF3 Female Advanced 70 0.56 0.6 0.92 1.2
AM3 Male Advanced 74 0.36 0.38 0.98 1.6
AM4 Male Advanced 80 0.32 0.32 0.4 0.75
AF4 Female Advanced 82 0.56 0.58 1.32 1.15
AMD age-related macular degeneration, VA logMAR visual acuity, CS Pelli−Robson log contrast sensitivity
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you’ve got cataracts, we’ll do something with you. But
… he said to me you have got cataracts but they’re not
bad … we wouldn’t touch them anyway, because with
the macular you let more light in and it will be even
worse still for you. So that was a really big worry, that
was.’ (AM4)
For some patients, diagnosis of a condition that was not
yet affecting their vision or daily routine, and that many
were unfamiliar with, was not particularly concerning:
‘It didn’t mean anything to me and since then I’ve
discovered my grandfather and my aunt and uncle …
have all had it.’ (AF1)
‘That was the start of it so to speak. I had been
diagnosed prior to that but as I say I didn’t take any
notice because it was only in one eye and even that
wasn’t bad.’ (AM1)
Some compared their diagnosis to other medical
conditions:
‘He tried to explain it to me kind of thing but … it
wasn’t affecting me so I wasn’t bothered. As far as I
was concerned it could have been a cold.’ (AM1)
‘It’s like hearing about Crohn’s disease. You know, if
you haven’t got it or if you don’t know anyone who’s
got it, you don’t know what it is. You just—I mean I’m
sure I’ve heard the name of it like I have Crohn’s but I
hadn’t got the least idea what it really does to
people.’ (AM3)
‘That wasn’t good news for me to hear that I had got
it but on the other hand I was early stages and I
wasn’t that upset because it wasn’t affecting me that
much. It was like knowing you’re going to get
arthritis; I know I’ll get arthritis one day I
suppose.’ (EF3)
Information about AMD was sought from peer support
groups (e.g., the Macular Society), from friends or family
members with AMD, directly from eyecare professionals,
from the Internet and from leaﬂets available in hospital eye
clinics:
‘I hot-footed it to Google and found out about
it’ (EF2)
‘I’d remembered years ago [name of friend omitted]
saying she had a problem with her eyes, we had
children at school together. I said oh is it glaucoma,
she said no you won’t have heard of it. Then through
this I said oh I’ve got that, it’s AMD.’ (IF3)
‘I discovered that there was a Macular Society and I
rang them actually. They were very helpful, I must
have been on the phone for nearly an hour with him
and then they sent me lots of leaﬂets and things. Then
I found we had a local group so I joined that.’ (IF6)
Participants also spoke about the impact of being diag-
nosed with dry AMD as an untreatable condition:
‘At the end of the day he just said you’ve got dry
macular degeneration, end of story and that’s how he
put it; end of story. So I said to him, what do you
mean end of story? He said well that’s it, there’s
nothing we can do, there’s no cure for it so there’s
nothing we can recommend you do, which is quite a
big shock.’ (AM4)
‘I don’t hold out a lot of hope although I do have a
little spark that maybe something can be done
eventually about it.’ (IF2)
Impact on everyday life
Daily activities Several domains of everyday life were
reported to be affected by dry AMD. One important
everyday task described by some participants was reading:
‘Reading is the main thing. Simple things like undoing
a package or … if I need to see detail. Cooking
instructions on a jar, reading any sort of labels, going
to the shops, seeing the signs over the aisles in a
supermarket.’ (AF1)
‘I just can’t read the way that I used to read. I can
only just read for a few minutes’ (AM2)
Another domain of everyday life identiﬁed as important
to participants was issues relating to mobility. Some
participants recalled falls related to their vision:
‘I have to be very, very careful that I don’t—actually
going up and down stairs. I did have a very bad fall
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some years ago and broke my wrists and that was
because I didn’t see.’ (AM3)
‘I don’t walk anywhere where there are tree roots or
stuff like that because over the last 12 months I’ve had
a couple of falls. So now I walk on paths, recognised
paths… if ever the situation arises where I am going
to be walking amongst trees, and you do get that
situation sometimes, I walk a lot slower and I’m
careful where I put my feet.’ (AM1)
Others had not experienced falls but found walking
particularly worrisome:
‘You feel very insecure out of doors. You can’t see the
edges of pavements. People whizzing past you on
bicycles on the pavement are a nightmare… You have
this tendency not to panic but to get into a sort of mini
panic situation especially when you don’t know where
you are… Also crossing a road, no matter how used
you are, when you get to the other side your heart is
racing which is, you know, odd. You can’t help
tensing up. You feel very vulnerable.’ (AF4)
Many current drivers voiced concerns about vision while
driving:
‘I can still drive, I can still see… now I only drive
where I know I’m going to and I know the road. If I
have to go say the other side of the river I would not
venture… because I couldn’t see the signs in time to
change lanes or go this way or that way.’ (IF13)
‘I still drive but I don’t drive far, I can’t see any signs
on the side of the road. I only drive [when] I know
where I’m going. I won’t drive anywhere else because
I’m worried about—I can see driving, I can see the
car in front. I probably couldn’t read the number
plate but I can see the car. I think that concerned me a
lot. I used to give people lifts but I don’t
anymore.’ (IF6)
‘I don’t really like it evening so much now I used to
love—that was my favourite time to drive. Now I do
ﬁnd that I’m not so comfortable with that. I prefer to
be in daytime.’ (IF3)
‘I will not pass the driving test anymore, so it means
within 6 weeks to 2 months I will not be able to drive
anymore. Driving to me has been one of the great joys
of my life because I love driving, I love nice
cars.’ (AM4)
Whilst others had given up driving completely:
‘I’ve missed the car most. You know the feeling when
you’re going to make something and you realise ah, I
haven’t got enough milk or I haven’t got enough that.
Before I could just jump in the car and pop to
Sainsbury’s or wherever but I haven’t got that ability
now so I’ve got to remember everything. I feel there’s
not much good writing a list because I can’t read it so
I have to remember it.’ (AF3)
Navigating public transport was particularly difﬁcult for
some participants:
‘When a bus is coming towards me I can’t see what
number it is until it’s almost upon me and it’s almost
too late to put my hand out. So I found myself stopping
busses and it’s not been the right number at all.
Actually in Hammersmith the last time I was up I got
on the wrong bus.’ (AF3)
‘I nearly got run over by a double-decker bus. It was
foggy and the bus was painted pale blue and white
and although I was looking towards it I did not see
it.’ (IF11)
Pastimes, for example, playing bowls, golf, watching
television, knitting, sewing, birdwatching, star-gazing, play-
ing music, gardening, eating at restaurants and visiting
exhibitions and galleries were all affected by participants’
vision loss. One participant described how she was able to
track the progression of her dry AMD with her ability to sew:
‘I used to make pillow lace. Perhaps 3 years ago, I
started a big piece. When I started, it was easy. By the
time a year had gone by and I was ﬁnishing, I couldn’t
really see the holes to put the pins in. That was about
2 years ago, 3 years ago. So I’ve had to stop doing
pillow lace making, which is sad. I can’t see to thread
needles.’ (IF7)
Another participant related how she did not want to reveal
the extent of her visual loss to her family:
‘The other thing that I really love is looking at the
stars. …I’ve got a son who lives near Ashdown
Forest… there’s no ambient light. The stars are
absolutely fantastic there. I go down with him … and
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we go out and look at the stars. They say, oh look,
there’s such and such a constellation, there’s another
one. I’m saying, oh yes, oh yes, but I can’t really see
it.’ (IF6)
Finally, some participants talked about difﬁculties with
self-care and everyday tasks at home, such as cooking and
cleaning:
‘Little cleaning jobs at home, my wife will always say,
you missed that and I didn’t see it.’ (AM3)
‘I shave with an electric razor… I take the head off,
undo the head and then clean it out that way, blow it
with a brush and all the rest of it. But I can’t do that
anymore because I can’t see how to undo it and I
can’t locate it back again because I can’t see where
they are.’ (AM4)
Emotional impact Diagnosis was often a hugely emotional
experience and many talked about trying to stay positive
directly following their diagnosis:
‘Mentally when I was ﬁrst diagnosed I was very upset
about it because I thought I would actually go blind. I
know now that I will probably keep my peripheral
vision but I hope it doesn’t come to that. I ﬁnd that
quite—the thought of having big gaps. I’ve got small
gaps now, I don’t really want them to get any bigger
[laughs]. I’d ﬁnd that—if I lost my independence that
would be the main thing, it’d cause me a lot of
distress. But no doubt I’ll try and get round it.’ (AF1)
‘It was a tremendous psychological shock. I used to
write stuff about how I felt, I felt very devastated by it
and then gradually you realise it’s not happening
immediately and you can go on doing everything
normally.’ (AF2)
‘When I was ﬁrst diagnosed, I was quite devastated
because I thought, oh gosh, I don’t want to lose my
eyesight… but it hasn’t got worse, so I’m lucky really.
I know people—and I know people with very little
vision at all who get around very well and live good
lives and have everything adapted and everything. So
it doesn’t worry me now, especially my time of
life.’ (IF6)
Following diagnosis, fear for the future was still an
important factor in some people’s lives, although most had
learnt to manage this:
‘My life has not changed at all. If I stop and think
about it too much, and what the future’s going to be
like, it’s not very nice. But I’m staying away from
those thoughts.’ (EF2)
‘Like I say, it doesn’t bother me per se. I don’t think
about it. Occasionally, I will think what if I woke up
tomorrow and—I don’t go on about it all the time,
because if I do, I’d probably send myself crazy.’ (IF8)
‘But I suppose it’s underlying anxiety that is going to
get worse, that’s the sort of emotional impact, yes. But
then there are other things I worry about as well so it
isn’t the ﬁrst thing I worry about.’ (EF3)
‘Well I am worried about getting dependent but I have
plans to counteract it.’ (IF2)
‘What’s the likelihood of my dry turning into wet? I
don’t know. I would take an overdose if that went
wet’ (IF11)
‘I was given a sheet, with a little dot in the middle and
the grid and I’m supposed to check that every day or
every week. Occasionally, I will take it out of the
drawer and do it. But I can still see the things moving,
little shapes move, or else there are empty spaces. So,
like I say, I have that in the drawer. I should have it
hanging up somewhere so I can just look at it, but I
don’t because again, if I did see something that—I
suppose what I’m trying to say is I don’t want to know
if there is something wrong, but I have to know, if you
know what I mean.’ (IF8)
Worries over driving were of particular concern:
‘Well I said about the driving, that’s where I shall
worry most that it will affect my driving.’ (EF3)
‘I’m aware of it every day and I worry about it to
some extent. I’d hate to have to stop driving.’ (AM3)
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Frustration was central to a number of people’s
experiences, frustration with oneself:
‘One of the problems then with AMD is that you ﬁnd
yourself sitting doing nothing, and thinking well, it’s
frustrating. There’s nothing you can do but you need
your eyes to do things.’ (AM2)
And frustration with others not understanding their
condition:
‘The better you are at coping with it … people get
fooled into thinking you can see more than you can…
you feel very much at a disadvantage and you cover it
up and then you get frustrated because you can’t see
things … you get irritated with people fussing over
you saying, are you all right? But then you get
irritated with them because they don’t realise that you
can’t see. So you’re kind of torn between people being
very—saying, oh, let me help you, you know, be
careful when you know you can cope. But then when
they sort of say things like, well you have a look over
there, you can see the sign and you know you can’t,
that’s also frustrating.’ (AF4)
‘When you go to a family get-together and they’re
producing photographs and they’re ignoring you.
That’s upsetting as well; they’re ignoring you. If it
was me and you were a sufferer I would be saying
we’ve got a photograph here and it’s your grand-
mother on and her dogs and your grandfather on and
he’s talking to them so to speak and you feel included
then.’ (AM1)
‘Going out with my family. They all know of course
but they don’t remember and I have to say hold on
please, come and help me, I can’t see this. It’s
frustrating for me and for them.’ (IF11)
Coping strategies
Strategies involving others Support from others helped
many people cope with their vision loss, whether family,
friends or strangers. Participants talked about becoming more
reliant on their partners in both positive and negative ways:
‘I’m not looking forward to getting any worse, but I
know I’m going to get worse, but as long as I’ve got
the tools to be able to do things I want to do, then ﬁne.
As long as [my wife]’s about, then that will be
super.’ (AM4)
‘All the plans that I had for our family have all gone
and it’s now all reliant solely on [my wife]. She makes
the decisions and takes them here and takes them
there and I kind of think I hide in the background and
I didn’t—don’t like that.’ (AM1)
Other participants described the support they receive from
friends:
‘I’ve got very good friends who always know and they
put—I don’t have to ask them. They’ll just read the
menu to me to save me getting my phone, my torch out
on my phone which I did quite a lot in restaurants but
if I’m with my friends that I know and read the menu
to me.’ (AF1)
Participants also stressed the value of asking strangers for
help where required:
‘I had to ﬂy to Belfast last year. When I came to come
back I couldn’t see my ﬂight. I could see the actual
board, I couldn’t read so I had to ask one. I ﬁnd that I
have to ask people quite a bit, is that the right place or
so I have to ask. As a rule people don’t mind so I have
to ask more about things.’ (AF1)
‘I don’t mind asking for help in a supermarket. I
landed at Reading station once expecting my son and
couldn’t work my mobile phone and I asked the
youngest policeman.’ (IF11)
Personal strategies As well as talking about help from
others, many participants described ways in which they had
personally changed how they go about certain activities.
Some found organisation such as sticking to set routines and
keeping the home tidy to be useful:
‘I suppose I stick to routines. Because if I have a new
breakfast cereal or breakfast thing, I’ve got to look at
the recipe on how to heat it up or whatever. That’s
difﬁcult.’ (AF3)
‘I’m alright indoors because I know where everything
is. I’m a fairly tidy person anyway but I’ve—no, I
know where everything is.’ (AF4)
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‘When cleaning my teeth I was losing the toothpaste
in the sink and I think most was going in the sink
rather than on my toothbrush. So then I discovered if I
put the toothpaste directly in my mouth—as long as
it’s only you using the toothpaste it doesn’t matter—
put it directly in my mouth and then brush my teeth… I
had wasted so much toothpaste’ (AF3)
Slowing down and taking things more carefully helped
some participants:
‘When I’m cycling I’m no longer reckless. I tend to be
slower and look at things harder.’ (EF1)
‘I wouldn’t have thought about pulling out and
overtaking, without looking, obviously but now I’ll
check, check and check before I do it. I don’t trust my
ﬁrst glance at anything. So I don’t do that very, often,
drive that number of miles. I tend to like to drive
where I know as well.’ (AF1)
‘I have to slow down… and I have to pay attention
more to what I’m doing… I have to just focus on one
thing at a time and see what it is that I’m
doing.’ (AM2)
Participants talked about how technology had helped
with managing their vision loss. Some reported increasing
the font or changing contrast or brightness on their
Kindles and iPads. Others had bought large screen
televisions and computer screens in order to optimise
vision.
Many participants reported always carrying a magniﬁer
and/or torch with them. Speciﬁc purpose-made low vision
aids were discussed:
‘Until recently when the person from Somerset Sight
came and visited me at home when I was making a
drink I would—sounds horrible doesn’t it. I’d put
my thumb over it like that then I’d know when the
water came up and burnt me, then I knew I had
enough water in there. He’s since given me a little
thing that you put on the side of the cup and it tells
you when the liquid has come up to the right
level.’ (AF3)
‘I’ve been to Surrey Sight and they’ve been very good.
I got my watch there and my salt and pepper, put a
red thing which is the salt and which is the pepper,
things like that, yeah.’ (AF2)
Lighting was important to most participants; some
described difﬁculties with bright light, while others talked
about their difﬁculties seeing in dark or dim light:
‘Oh well, I like a bright light. I don’t—I struggle—I
can do it very often but if I’m going to read a book or
something, or I’m reading in bed I like the light pretty
bright. I don’t like, personally, very dim rooms.’ (IF1)
‘I don’t go out at night mainly because of not being
able to see very well, kerbs and steps and what-have-
you are difﬁcult. Going to the cinema, I always have
to stand at the back for absolutely ages before I can
see my way to the seats or anything and that goes for
the theatre as well but I go to the cinema quite often,
most weeks.’ (AF3)
‘Probably after about a minute in a shop I might be
better, but sometimes I’m just completely blind from
out of light into dark and sunlight’s terrible, I hate
sunlight.’ (IF6)
‘Sometimes when I just can’t pick out the words on
something I’ll actually have to use a torch… it has to
be a good light to see in, though the paradox is that
the eye—the light upsets my eye. But so it’s a double-
edged sword.’ (AM2)
Finally, some participants described head or eye move-
ment strategies that improve their vision:
‘When I talk to anybody invariably I’m doing what
I’m doing with you; I’m looking over their shoulder.
Because then I can see more of their face.’ (AM1)
‘Well sometimes when I turn my head I can see
perhaps a little better but I don’t really have all that
many problems.’ (EF1)
Discussion
The vast majority of people with AMD are living with the
non-neovascular (dry) type. Yet this study was the ﬁrst, to
our knowledge, to qualitatively investigate the patient
experience speciﬁcally of dry AMD. Many of our partici-
pants had relatively good measured visual function; for
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example, more than one half satisﬁed VA requirements for
holding a UK driving license. Yet, in our results, several
domains of everyday life were reported to be affected by
dry AMD. These domains related to psychological well-
being as well as ability to perform activities of daily living.
Many participants reported feelings of distress at the time of
diagnosis, with many reporting a fear of going blind, and a
perceived lack of empathy from their eyecare providers. A
common theme among participants, particularly those with
GA, was a feeling of social isolation due to their visual loss.
A thread running throughout all of the themes was the
uniqueness of dry AMD as a chronic, untreatable and
slowly progressive condition. Participants described hope-
lessness and despair following diagnosis and their knowl-
edge that things could only get worse and not better, even at
the stages when their vision was not yet signiﬁcantly
affected. This contrasts with other age-related eye condi-
tions, which, whilst causing signiﬁcant burden to the
patient, are treatable. For example, patients with progressing
glaucoma described positivity and conﬁdence in their
treatment and a feeling of being ‘in control’ because their
condition could be managed [31]. Similarly, patients with
nAMD have expressed guarded optimism, with some belief
and trust in injections maintaining their vision [32].
The results support our suggestion that the psychological
impact of diagnosis of dry AMD differs from that of nAMD,
in that many patients are unaware of any visual disturbance
prior to diagnosis, and diagnosis is often incidental at a
primary eyecare appointment, or secondary eyecare
appointment for another condition. Patients must then live
with the insurmountable fear of their condition worsening.
Studies in the ﬁeld of glaucoma suggest that fear of disease
worsening may have a signiﬁcant impact on newly diag-
nosed patients’ quality of life, regardless of VA and visual
ﬁeld scores [33, 34]. This is worthy of further investigation
in dry AMD and should be the focus of future work.
Some participants expressed discontent with the way their
condition had been diagnosed and/or managed by their
healthcare professional. This aligns with research conducted
previously in AMD (not speciﬁc to dry AMD) and low
vision as a whole [5, 35, 36]. These ﬁndings are in line with
Boxell et al. [35] who report information and support pro-
vision at the time of diagnosis to be lacking in patients’
opinions, despite interventions such as improved guidance
for healthcare professionals [33, 34] being put in place since
a previous survey. In particular, sufﬁcient information for
newly diagnosed patients should be clear and accessible;
images widely used online to educate the public about AMD
are non-realistic for the majority of individuals with dry
AMD [37]; thus, ‘hot-footing it to Google’ after diagnosis,
as one participant related, may do more harm than good.
This study has several key implications for clinical
practice. First, there is a need for improved communication
between patients and healthcare providers, including written
information at time of diagnosis and psychological support
after initial diagnosis. Second, key information is also
needed for friends and family members, in order to mini-
mise embarrassing and difﬁcult social situations for both
parties. Further to this, peer support networks may be
beneﬁcial for people at any stage of AMD, but our results
suggest that individuals with early AMD may also ﬁnd
visiting peer support groups distressing. Several inter-
viewees said that they were not distressed by their diagnosis
immediately as many were asymptomatic, and the impli-
cations did not resonate. Going to a support meeting with
people with marked visual impairment would cause distress
by illustrating the potential pathway of the disease as it
progresses. Speciﬁc networks for people in the very earliest
stages of AMD may be useful. Finally, undiagnosed AMD
may present to a variety of primary and secondary health-
care professionals—it is vital that healthcare professionals
are equipped with the tools to manage this condition
appropriately.
We appreciate that it would be unrealistic to suggest that
eyecare professionals provide dedicated in-depth psycho-
logical support within the realms of a busy eye clinic.
However, evidence suggests that a few simple techniques
can be adopted in order to improve the experience of
diagnosis of dry AMD. For example, one recent study [38]
identiﬁed key considerations relevant to breaking bad news
in the ﬁeld of ophthalmology, including recognising and
aligning the expectations of patients to those of the practi-
tioner, and managing the impact on the patient of ‘extreme
sub-specialisation’ within ophthalmology, meaning that
often patients will be seen by several eyecare professionals
with inconsistent communication. Successful strategies for
breaking bad news were reported to be use of clear expla-
nations, including giving the patient a ‘road map’ for the
future, taking time with and empathising with the patient.
Those working in the eyecare setting ought to undergo
regular training on communication skills related to breaking
bad news. This may be beneﬁcial in regard to the positive
psychological effect on the patients of receiving bad news
in a sensitive manner, but also in minimising any detri-
mental effect on the practitioner responsible for breaking
the news [38, 39].
Rehabilitation pathways should be standardised and
consistent across the eyecare sector; this information should
then be made clear to patients. Evidence suggests that
eyecare professionals’ views on the importance of rehabi-
litation services is variable [40]. Moreover, there may be
confusion over who is responsible for advising patients
about such services [40]. As a result, patients may be left
unaware of support networks that are available to them [41].
One solution might be to ensure all individuals with dry
AMD are referred to an Eye Clinic Liaison Ofﬁcer (ECLO),
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whose role includes discussing information about eye con-
ditions, education and employment, providing emotional
support to patients and their family members, and referring
patients to other relevant support services such as coun-
selling or social services [42, 43].
Our study is the ﬁrst to investigate the experience of
living with dry AMD using qualitative methods. Yet, our
study has limitations. All participants were volunteers who
responded to a call for participants; it is likely that this has
biased the views represented in our study. Furthermore,
participants were able to travel to central London for their
study visit. Subsequently, we may have underestimated
problems with mobility and isolation in the general dry
AMD population. Participants were also required to be in
relatively good general health with no ocular comorbid
conditions—many patients with dry AMD are living with
other conditions which may exacerbate problems; this
would not have been captured using our study design. In
addition, our logMAR VA cut-off of 0.7 would have
excluded those with advanced central GA. Moreover, the
median binocular VA of our participants of 0.2 (Snellen
equivalent of 6/9.5 or 20/32) was relatively ‘good’. How-
ever, it is well-evidenced in the literature [44] that VA may
not be the best measure of an individual’s visual function in
early and intermediate AMD, and that VA may remain
‘good’ whilst other measures of visual function (such as
dark adaptation) decline. Recall bias may have inﬂuenced
our results; particularly with respect to recall of healthcare
visits as patients’ recall of clinical consultations is reported
to be poor [32, 33]. Whilst this may have affected the his-
torical accuracy of the patient reports, the overall message
that more needs to be done to improve this experience for
the patient remains. Finally, our convenience sample, con-
sisting mostly of female respondents with intermediate
AMD, is not likely to be completely representative of a
population of people living with the condition.
To conclude, dry AMD has some unique burdens on the
patient that may require speciﬁc and tailored management
strategies. Diagnosis itself, regardless of vision loss, may
cause a signiﬁcant psychological burden related to fear and
a noteworthy anxiety about the condition worsening. Fur-
thermore, self-perceived impact on daily life may be con-
siderable even while clinically measured visual function
remains relatively good.
Summary
What was known before
● Dry AMD is a widely prevalent, gradually progressive
condition with no currently available treatment.
● Qualitative research is a useful methodology for
investigating the impact of a condition and for shaping
future research and practice.
● To date, no studies have qualitatively investigated the
impact of dry AMD on the patient.
What this study adds
● Diagnosis of dry AMD results in signiﬁcant psycholo-
gical burden for the patient and many fear ‘going blind’.
● Perceived impact on daily life may be considerable
whilst measurable visual function remains reasonable.
Improved support is needed for patients, both directly
following diagnosis and in the longer term.
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